Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bismuth-based Susceptibility-guided Therapy for MDR H. pylori
NCT06687473Phase 4Completed
- Sponsor
- National Cheng Kung University Hospital
- Start
- Jan 2022
- Primary completion
- Mar 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bismuth subcitrate in Helicobacter pylori infection, sponsored by National Cheng Kung University Hospital. Primary endpoint: Eradication rate of H. pylori. Started Jan 2022; status: completed.
02
Drugs
bismuth subcitrate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT06687473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06687473.